Although targeted therapy has been successful in the treatment of cancers such as EGFR- or anaplastic lymphoma kinase (ALK)-mutated non-small-cell lung cancer or BRAFV600E-mutated melanoma, targeting these mutations has been largely ineffective in glioblastoma. The gene discussed is ALK; the disease is melanoma.